BidaskClub lowered shares of Vital Therapies, Inc. (NASDAQ:VTL) from a buy rating to a hold rating in a report published on Thursday.
A number of other research firms also recently weighed in on VTL. Zacks Investment Research downgraded Vital Therapies from a hold rating to a sell rating in a research note on Tuesday, October 31st. ValuEngine raised Vital Therapies from a strong sell rating to a sell rating in a research note on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $8.00.
Vital Therapies (NASDAQ:VTL) traded up $0.15 during mid-day trading on Thursday, reaching $5.85. The company had a trading volume of 87,200 shares, compared to its average volume of 146,199. Vital Therapies has a fifty-two week low of $2.25 and a fifty-two week high of $6.50.
Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. During the same period last year, the company earned ($0.32) EPS. analysts anticipate that Vital Therapies will post -1.29 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2017/11/13/vital-therapies-inc-vtl-downgraded-to-hold-at-bidaskclub.html.
In other Vital Therapies news, Director Muneer A. Satter bought 50,000 shares of Vital Therapies stock in a transaction dated Friday, September 8th. The stock was bought at an average cost of $3.53 per share, with a total value of $176,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime bought 10,000 shares of Vital Therapies stock in a transaction dated Wednesday, September 13th. The stock was acquired at an average cost of $4.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director now owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Over the last three months, insiders bought 190,000 shares of company stock valued at $737,800. Company insiders own 32.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after acquiring an additional 1,157 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after acquiring an additional 9,120 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Vital Therapies in the third quarter valued at approximately $116,000. Victory Capital Management Inc. grew its holdings in shares of Vital Therapies by 0.9% in the third quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock valued at $13,145,000 after acquiring an additional 23,810 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Vital Therapies by 1,985.3% in the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock valued at $123,000 after acquiring an additional 24,241 shares in the last quarter. 25.73% of the stock is owned by institutional investors.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.